Classical genetic research approaches to determining the genetic contribution to a multifactorial condition have been used to quantify the proportion of addiction and substance abuse that is a result of heritable genetic factors versus environmental factors. Family studies, twin studies, and adoption studies have all been applied for individuals and families with a history of addiction and substance dependence. As a whole these studies estimate that there is a 40% to 60% heritability for addiction and alcoholism. 1, 2 Family studies are used to assess the heritability of addiction by examining the risk of addiction in relatives of a known affected individual. Studies of alcoholism and other drugs have showed that first-degree relatives of individuals with addiction are at an increased risk to develop an addiction problem, compared with individuals without a family history.
1,2
Family studies are used to assess the heritability of addiction by examining the risk of addiction in relatives of a known affected individual. Studies of alcoholism and other drugs have showed that first-degree relatives of individuals with addiction are at an increased risk to develop an addiction problem, compared with individuals without a family history. 3 Family studies are often limited in the ability to exclude common environment factors shared in families such as living environment, socioeconomic status, and stressor events.
Adoption studies serve as a tool to limit the shared environmental factors that arise in family studies by investigating individuals raised by nonrelated adoptive parents. Numerous studies of alcoholism have suggested that children with a biological family history of alcoholism raised by nonalcoholic parents are at an increased risk for developing addiction as compared with adopted children without a family history of alcoholism. 4, 5 These studies support the genetic liability of addiction despite family environments absent of an addicted parent.
Twin studies are valuable in investigating both genetic and environment factors by studying concordance of addiction between monozygotic (identical) and dizygotic (fraternal) twins. Because monozygotic twins inherit the same genome, a higher rate of concordance would be expected for a genetically determined condition and a lower concordance rate in dizygotic twins that share 50% of genetic information. For primarily environmentally mediated conditions, the concordance rate between both twin types raised together should be similar. The twin studies that have investigated abuse of alcohol, nicotine, and other drugs have showed a greater concordance rate between monozygotic twins, raised together or apart, versus dizygotic twins. [6] [7] [8] This finding again strongly supports the notion that a significant portion of addictive behaviors are the result of inherited factors. ' 
Molecular Approaches to Identifying Genes for Addiction
Although there has been extensive research since the 1990s to identify ''the'' gene for alcoholism, nicotine addiction, and other types of drug addiction it has proven generally illusive. Many candidate genes have been identified, however, none have proven responsible for a significant portion of addiction in diverse populations. Similar to other multifactorial conditions, it is unlikely that any one gene will be responsible for a significant fraction of the heritable factors that mediate addiction owing to the complexity of the biological pathways involved. Below is a summary of common approaches that attempt to identify specific molecular genetic factors that influence addiction.
Linkage Studies
Linkage studies are family-based studies that track phenotypes (physical characteristics or specific disease) and genotypes within a family for a particular condition. These studies do not identify specific genes but regions of the genome that may harbor an important gene. 9 As an example, large studies such as the Collaborative Study on the Genetics of Alcoholism (COGA) have used linkage to identify specific regions of numerous chromosomes that may include genes associated with alcoholism and other substance abuse markers. 1, 10 Identification of hot spots within the genome for possible genes that play a role in familial addiction changes can be further explored to identify specific genes.
Candidate genes are identified based on positional cloning of regions identified by the linkage studies and functional cloning of genes involved in known pathways. For example, functional genes have been studied in the g-aminobutyric acid (GABA) inhibitory neurotransmitter pathway and in the pathway for the metabolism of acetaldehyde in alcoholism. 7 This approach, using modern sequencing technology, has resulted in the identification of a multitude of potential genetic factors for addiction to alcohol, nicotine, opiates, and other substances. Candidate genes for alcoholism and alcohol-related phenotypes have been identified on every chromosome except for the Y chromosome. [10] [11] [12] The vast number of candidate genes reinforces the complexity and polygenetic nature of addiction's genetic basis.
Genome Wide Association Studies
Genome-wide association studies (GWAS) are nonhypothesis driven studies of the genome that search for candidate genes in a specific phenotype by comparing the genetic pattern of unrelated individuals with a specific condition to those without the condition. 13 GWAS have been applied to the study of many complex multifactorial conditions by investigating large portions of the genome based on known single nucleotide polymorphisms (SNPs) for changes that correspond with the condition of interest. These studies produce large amounts of data that have to be further evaluated. Once an area of interest is identified in the genome for investigation, it then has to be replicated in an independent sample population to prove or disprove the association, and then additional genotyping and deep sequencing of the region to investigate the possible variants within the gene must be done.
14 GWAS have been applied in alcohol dependency, 15 nicotine addiction 16 and drug abuse, and addiction 17 all of which have provided new areas of exploration and validation of candidate haplotypes.
Epigenetic Studies
Epigenetics is an expanding region of interest in the study of addiction and substance abuse because it explores the impact of specific addictive substances on the cellular environment of the brain. Epigenetic factors are heritable changes in gene expression that occur without a change in DNA sequence. Common epigenetic mechanisms include DNA methylation, histone modification, and chromatin remodeling. 18 Studies of epigenetic mechanisms on addiction 19 and alcoholism 20 have exhibited that the exposure of cells in the brain to potentially addictive substances have significant and lasting impact on chromatin structure and subsequently impact the individual behavioral response to these stimuli. This area of research promises to provide insight into addiction at a cellular level and identify possible pharmacogenetic targets for the treatment of addiction. 
Neurobiologic Mechanisms
Drug addiction has been described as a disease of the brain reward system wherein drugs activate the neuronal circuitry involved in reward and memory. 21 This activation produces an abnormal activation of the learning process and results in a ''highjacking'' of basic neuronal processes in the brain 22 that ultimately results in loss of control over drug intake and significant impairment in functioning. Chronic drug use induces changes in neuron structure and function that may last for weeks to years. A destructive spiral begins as the pleasurable effects of an abused drug are dampened while at the same time cravings increase. This pathologic disorder of learning and memory is likely established by genetic predispositions and drug-induced neuroadaptations in the brain's reinforcement systems. 23 For years laboratory animals have provided insight into a common pathway for the progression of addiction. Rats, mice, and even nonhuman primates will self-administer the same substances that humans abuse. 24, 25 These animals are connected to an intravenous line, which will administer a drug when a lever is pushed whereas another lever provides saline and yet another provides food. Within a few days the animal will readily self-administer the addictive substance and spend most of their waking hours working to obtain more, even if it means pressing a lever hundreds of times for only 1 dose. And just as humans associate triggers, paraphernalia, or external stimuli, with anticipatory pleasure, animals also come to prefer an environment, maybe a corner in the cage, where lever pressing produces drug administration (euphoria). If the substance is removed the animal will end laboring for the chemical but after a long time of abstinence, even months, he will immediately return to its lever pressing behavior when given just a taste of the chemical or placed near a trigger. In addition, animals run to the lever whenever they are exposed to any psychological or physical stressors such as foot shock. 26, 27 A major challenge is to understand why many people engage in prolonged recreational use without progressing to compulsive use and almost complete disregard for its harmful consequences. It has been estimated that as few as 20% of people who use cocaine actually become addicted. 28 Higher numbers are reported for other drugs of abuse.
'

Theories of Addiction
The causes of abuse and addiction are complex and multifactorial including social, economic, and genetic factors. Even so, animals not affected by the same social and economic variables as humans voluntarily self-administer the same drugs, which is a compelling argument for the biologic basis of addiction. Obvious questions arise such as ''Why would a person continue in an obviously self-destructive and aberrant behavior?'' These questions are not easily answered and would likely be viewed differently by various professional interests. Scientists search for causative factors that initiate and perpetuate the behavior whereas clinicians search for the ways to modify the behavior to benefit the patient.
Theories of motivation began as early as the 19th century and posited that there are primary subconscious instincts encoded in us that propel our behavior and cannot be modified. In the 20th century, motivational theories proposed that internal homeostatic brain mechanisms are activated in substance abusers that drive the aberrant behavior and pharmacologic intervention could possibly inactivate these same mechanisms. The idea of an ''addictive personality'' was birthed and offered that these individuals have a preexisting psychic disturbance that propels drug-taking behavior. None of these motivational models satisfactorily explained all aspects of compulsive behavior but did lead to the mid 20th century reinforcement theories sparked by the works of B.F. Skinner. 29 Reinforcement theories are based on the hypothesis that the goal of an organism is to learn to act in such a way as to maximize future rewards and postulates that there exists a relationship between random behavioral elements and environmental stimuli. 22 Environmental stimuli are thought to act as reinforcers that, when paired with a particular behavior, will increase the future probability of that same behavior. Essentially, the reinforcing stimuli act on the central nervous system to alter the future probability of repeating the behavior. The reinforcement theory for substance abuse posits that compulsive substance use is the result of positive reinforcers from past experiences. Positive reinforcers activate pleasurable, or rewarding, internal neural processes sought by substance abusers as a ''high'' or ''rush.'' This brainstimulation reward phenomenon has been amply confirmed for more than 4 decades and seems to be an essential commonality among abused substances. The reward model based on positive reinforcement is currently the most compelling hypothesis available on the neurobiology of substance abuse.
Although positive reinforcement theories (''pleasure seeking'') are a leading model of study, other models emphasize unique aspects of addictive behaviors. 30 These signs include negative reinforcement (''pain avoidance''), stimulus response learning (''habits''), inhibitory control dysfunction (''impulsivity''), and incentive salience (''craving''). It is likely that in any substance abuser 1 or more of these models are at work and that among substance abusers as a group the causes are heterogeneous. Two of the extensively researched models, positive reinforcement and negative reinforcement are discussed below.
Positive Reinforcement and Reward Processing
In the wild, animals spend most of their time engaged in goaldirected behavior necessary for their survival. These behaviors, such as food seeking, caring for young, or seeking sexual partners, are driven by emotions that encourage beneficial outcomes. Emotions may be positive (pleasure, reward, hedonism) and will encourage continued behavior or negative (pain, suffering) and will discourage behavior. Positive emotions serve as positive reinforcers, increasing reward value, and the probability that the animal will engage in the behavior again. Reward value can be described by at least 3 different parameters: (1) magnitude, (2) probability of occurrence, and (3) quality, that is, incentive or saliency. 31 Natural rewards experienced from daily activities, eating, sex, etc. are described mostly by magnitude and probability, whereas drugs of abuse tend to create a higher incentive value and therefore are more likely to result in addictive behavior.
The reinforcing properties of abused drugs along with environmental factors are thought to be responsible for the initiation of drug use. With repeated use, however, complex interconnected neural mechanisms occur that lead to craving and dependence and encourage continued use of the drug. Neural circuitry responsible for reinforcement, craving, and dependence is found in the mesolimbic dopamine system and the opioid system.
Mesolimbic Dopamine System
The mesolimbic dopamine system is a set of neurons that originate in the ventral tegmental area (VTA) and send projections to target regions in the more anterior portions of the brain, most notably the nucleus accumbens (NAc) found deep beneath the frontal cortex. These mesolimbic dopaminergic projections are thought to be a primary mediator of positive reinforcement experienced with drug-seeking and drug-consuming behaviors. 32, 33 The precise role of dopamine (DA) in motivational behavior is not totally clear and is still a matter of considerable debate. Even so, it is known that animals with lesions in the mesolimbic DA pathways no longer show interest in substances of abuse. 34 Early theories of DA function suggested that as synaptic concentrations increase in the NAc, a hedonic signal (signaling pleasure) is processed. Although there is some correlation between synaptic concentration of DA and hedonic signaling, there is little evidence to support this identification as the primary role of DA. 35 Instead, DA seems to mediate phasic bursts of mesolimbic neuron firing that promote reward-related learning by linking the hedonic properties to desires and actions, thus shaping subsequent reward-related behavior. 36 In addition, DA likely plays a role in transferring incentive salience to reward-related stimuli, overcoming aversive effects, and modulating the reward mechanism. 37 Cocaine and other stimulants are known to affect the release and reuptake of DA and with repeated, chronic use a compensatory change occurs in dopaminergic neurotransmission. Using PET scanning Martinez et al observed a modest decrease in DA receptors but a substantial reduction in DA release in response to amphetamines in participants with a history of chronic cocaine use. 38 The reduction was most noticeable in areas of the basal ganglia responsible for mediating emotion and choice. In chronic cocaine addicts, upregulation of surface DA transporters, responsible for translocating extraneuronal dopamine back into dopaminergic neurons, are likely responsible for much of the negative symptoms (depression) experienced during withdrawal and the progressive decline in euphoria (tolerance) seen over time. 39 Limited preclinical trials indicate that dextro (D)-Amphetamine and other substrates that cause internalization of DA transporters are useful in amerliorating symptoms of cocaine withdrawal and reducing cocaine consumption and craving. 40 Functional polymorphisms in DA transporter genes result in genetically induced variations for anticipation and reward-process and likely contribute to individual differences in predisposition to drug-seeking behavior and other psychiatric disorders. 41 Dopamine agonists are routinely prescribed for Parkinson disease, certain pituitary tumors, and even restless legs syndrome. Although euphoria and hallucinations are reported side effects of these agents, prescribed patients typically do not experience the dopaminergicmediated reward (''high'') as do substance abusers. This negative experience can be accounted for by differences in baseline DA system functioning. 42 Animal research has shown a ''Goldilocks zone'' of DA receptor stimulation such that too little or too much stimulation of DA receptors decreases neural reward mechanisms. Individual variability in baseline DA system functioning is likely owing to an inverted-U relationship between DA receptor gene (Taq1A DRD2) polymorphism and drug effects. 43 These findings provide a strong link between genetics, drugs, and neural activity.
It has been hypothesized that impulsivity may be mediated in part by DA receptor dysfunction in the NAc. 44 Impulsivity leads to drug binging and is implicated in the development of compulsive drugseeking behavior. The importance of DA receptors in reinforcing effects of abused drugs is also shown by the inability of DA receptor knockout mice to reliably acquire cocaine self-administration. 37 Although the focus of drug reinforcement mechanisms has been on DA-dependent mechanisms (specifically the VTA), there is emerging evidence that dopamine fails to fully explain some areas of the reward process. [45] [46] [47] It is clear that dopamine is involved with motivational and learning aspects of drug reinforcement but the role of DA in hedonic responses is no longer emphasized. Brain regions expressing opioid receptors seemed to be more involved with hedonic responses and can likely be explained with clarification of the interaction between DA and the opioids.
Opioid System
The opioid system is central in the mediation of nociception, analgesia, and pain pathways. In addition, the opioid system regulates numerous physiologic functions including stress response, respiration, endocrine function, immune function, and gastrointestinal transit. The complex neurocircuitry that confers pleasurable reinforcement in activities such as food intake, sex, and drug abuse are mediated partly by the opioid system. In recent years, the role of the opioid system in modulating mood and addictive behaviors has become apparent 48, 49 and is likely mediated by the opioid receptors and peptides that are strongly expressed in the mammalian brain reinforcement circuits.
Strong addictive properties of opiates were acknowledged soon after their discovery and use as analgesic and euphoric. Enkephalins, dynorphines, and b-endorphins are endogenous opioid peptide ligands for the opioid receptor gene family that includes mu (Oprm1), delta (Oprd1), kappa (Oprk1), and the nonopioid orphanin FQ/nociception (Oprl1) receptors. Opioid peptides and receptors are expressed throughout the central and peripheral nervous system. Mu, and to a lesser extent, delta agonists produce positive reinforcement, whereas kappa agonists induce aversion and hallucinations. As such, mu and delta antagonists suppress the positive reinforcement of natural rewards whereas kappa antagonists facilitate these effects. 50 In fact, animal models have shown that mu opioid receptor activation is necessary for the development of drug dependence in any class. 51 Pharmacologic activation or blockade of opioid receptors at several sites known to be involved in the brain reinforcement network has shown a role of these receptors in both the ''pleasure'' natural reward system and the reinforcing properties of abused drugs. 52 Brain sites in which opioid agonists or antagonists modulate drug reinforcement include the VTA, NAc, and ventral palladium (VP). Mu and delta receptors found in the VTA and NAc modulate positive reinforcement for both opioid and nonopioid drugs of abuse including ethanol, 53 cocaine, and nicotine. In addition, mu and delta receptor blockade leads to a decreased response when drugs of abuse are administered. 54 Most drug abusers progress through a variety of phenotypes beginning with recreational use, to compulsive use and finally abuse. These differences in phenotypes may be partially explained by selective inactivation of 6 genes that encode for opioid receptors. Repeated administration of morphine or alcohol resulted in downregulation of opioid peptides in many brain areas. 55 Stimulants, in contrast, upregulate the same set of genes suggesting that distinct drug classes produce different neuroadaptations of endogenous opioids. In the future, drug-specific genetic regulation may offer a solution for controlling or preventing relapse. 56 All together, pharmacologic activation of opioid receptors and genetic variation in receptor encoding establishes a role for the opioid system in the behavioral response to drugs of abuse, the drug reward system, and the mechanisms of dependence.
In addition to DA and opioids other neurotransmitters including glutamate, serotonin, and acetylcholine are involved in the experience and progression of drug use. Acetylcholine is involved in motor behaviors, emotional states, motivation, arousal, learning, and memory. The limbic and paralimbic regions of the central nervous system contain the highest density of acetylcholine innervations in the brain and are most relevant to addictive processes. 57 In animal models, cocaine acutely increases acetylcholine in the VTA, NAc, and dorsal striatum that complement DA input and heighten therewarding effect. 58 It is clear that acetylcholine and DA share a neurobiologic interconnectiveness but further investigations are needed to investigate the full scope of relevance.
'
Negative Reinforcement and Aversion Processing
Traditionally, the behavioral changes associated with drugs of abuse are associated with rewarding effects. However, these drugs also produce dose-dependent aversive effects that limit further use. Reward and aversion pathways are separate and the balance between the 2 predicts the likelihood and rate at which an animal will selfadminister. A highly rewarding drug with minimal aversive effects is more likely abused than a drug with less rewards and more pronounced aversion.
Conditioned taste aversion (CTA) is a way to index and document a drug's aversive effects. CTA serves a protective function and manipulations to this process may have implications for drug-taking behavior. Reports investigating CTA-inducing effects of commonly abused drugs such as alcohol, amphetamines, and morphine, and tetrahydrocannabinol (cannabis) show an ability of these drugs to support aversion learning as does other noxious stimuli like radiation, emetics, and other toxins. 59 The mechanism of CTA is less investigated than the reward system but is believed, at least for cocaine, to involve inhibition of the serotonin reuptake (SSRI) and serotonin transport (SERT). 60 Further understanding of the neurochemical and neuroanatomical mechanisms behind these aversive effects is necessary to elucidate treatments based on these mechanisms or to determine differences in susceptibility based on these effects. ' 
Conclusions
Advances in the understanding of molecular genetics and the new tools available to examine the genome have provided the researchers with the ability to extend genetic research in addiction. The complexity of the multiple pathways involved in addiction and the myriad of genetic and environmental influences highlight the need for ongoing research to expand our understanding of the addiction and improve treatment options. Future research will increase our understanding of how druginduced neuroadaptations interact with genetic predispositions. As with most multifactorial conditions, it is unlikely that one standard treatment paradigm will be effective for all individuals with an addiction. Advances in molecular biology and molecular genetics provide a promising opportunity for the development of personalized medical treatment for individuals with addiction that will include an evaluation of influential genetic variants and behavioral and environmental factors. 
